Search clinical trials for: JNJ 64304500

Total 1086 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Testosterone Greater Than 150 ng/dL

United States
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Janssen Sciences Ireland UC

Terminated

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA)

Respiratory Syncytial Virus Infections

United States, Belgium, Taiwan, Israel, Japan, Argentina, Malaysia, Korea, Republic of, Netherlands, Spain, Australia, Italy, Brazil, France, United Kingdom, Sweden, Bulgaria
Janssen Research & Development, LLC

Completed

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (AXIOMATIC-TKR)

Arthroplasty, Replacement, Knee

Israel, Belgium, Italy, United States, Spain, Hungary, Portugal, Russian Federation, Japan, Turkey, Ukraine, Greece, Poland, Argentina, Brazil, Bulgaria, Canada, South Africa
Janssen Research & Development, LLC

Recruiting

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States, Israel, Korea, Republic of, Spain, Czechia, France, Brazil, China, United Kingdom, Malaysia, Hungary, Japan, Poland, Germany, Ukraine, Italy, Greece, Netherlands, Egypt
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (GENESIS)

Dermatitis, Atopic

United States, Germany, Canada, Poland, Japan
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Healthy | Systemic Lupus Erythematosus

United States, Spain, Romania, Taiwan, Belgium, Poland, Moldova, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen-Cilag International NV

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy Volunteers | Pharmacokinetics

Belgium
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants

Healthy Volunteers

Japan
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (AZALEA)

Hemolytic Disease of the Fetus and Newborn

Israel, Brazil, Australia, United States, United Kingdom
Janssen Research & Development, LLC

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

United States, China, Taiwan, Korea, Republic of, Japan, France, Spain, Czechia, Poland, Greece, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Korea, Republic of, Japan, Taiwan, Denmark, Germany, Czechia, China, Spain, Belgium, Canada, Mexico, Poland, Italy, France, Australia, Sweden
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-61393215 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

Renal Insufficiency

Germany
Johnson & Johnson Enterprise Innovation Inc.

Recruiting

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-small-Cell Lung

Korea, Republic of, Spain, United States, Germany
Janssen Research & Development, LLC

Completed

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United Kingdom, United States, Spain, Germany, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection (OSPREY)

Hepatitis B, Chronic

France, Belgium, Italy, United Kingdom, Poland, Spain, New Zealand, Taiwan
Janssen Research & Development, LLC

Completed

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, United States, Malaysia, Turkey
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Acute Coronary Syndrome

Taiwan, Korea, Republic of, United States, Italy, South Africa, Belgium, Argentina, Israel, Malaysia, Romania, Serbia, China, Australia, Netherlands, United Kingdom, Denmark, Czechia, Hungary, Japan, France, Canada, Bulgaria, Spain, T... and more
Janssen Research & Development, LLC
Bristol Myers Squibb Company (BMS)

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)

Ischemic Stroke; Ischemic Attack, Transient

Italy, United States, Hong Kong, Japan, Taiwan, Korea, Republic of, Israel, United Kingdom, Argentina, Belgium, New Zealand, Canada, Germany, Denmark, Mexico, Croatia, France, Australia, Brazil, China, Czechia, Hungary, Netherlands, S... and more
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple Myeloma | Previously Treated Amyloid Light-chain (AL) Amyloidosis

Belgium, United States, United Kingdom, Spain, France, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, China, France, Denmark, Israel, Poland, Australia
Janssen Research & Development, LLC

Completed

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Spain, Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors

Neoplasms

Spain, Israel
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Janssen Research & Development, LLC

Completed

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers

Healthy

Netherlands
Janssen Sciences Ireland UC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B

United States, Korea, Republic of, France, Belgium, Italy, Taiwan, United Kingdom, Thailand, Malaysia, China, Spain, Canada, Germany, Japan, Russian Federation, Turkey, Ukraine, Poland, Hong Kong
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Advanced or Refractory Leukemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

Advanced Solid Tumors

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Spain, France, Canada
Merck Sharp & Dohme LLC

Recruiting

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Hepatic Impairment | Non-alcoholic Steatohepatitis

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, United Kingdom, Taiwan, Israel, Spain, Australia, France
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 (Amplify)

Coronavirus Disease

United States
Janssen Scientific Affairs, LLC

Available

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Multiple Myeloma
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-64300535 in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Japan
Janssen Research & Development, LLC

Terminated

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

Advanced Cancer

United States
Janssen Research & Development, LLC

Terminated

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Healthy | Asthma

United States
Janssen Research & Development, LLC

Completed

Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Alzheimer Disease

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

Canada, United States, Germany, Netherlands, Spain

Search clinical trials for: JNJ 64304500

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations